Suggested remit: To appraise the clinical and cost effectiveness of netarsudil-latanoprost within its marketing authorisation for treating open-angle glaucoma or ocular hypertension.
 
Status Proposed
Process STA 2018
ID number 1363

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators 28 September 2020 - 26 October 2020

Project Team

Project lead Emily Richards

Email enquiries


For further information on how we develop guidance, please see our page about NICE technology appraisal guidance